330 q 1999 Blackwell Science Ltd
|
|
- Jayson Cooper
- 5 years ago
- Views:
Transcription
1 British Journal of Haematology, 1999, 107, 330±334 Rabbit antithymocyte globulin (r-atg) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a rst course of intensive immunosuppressive therapy E. DI BONA,F.RODEGHIERO,B.BRUNO, A.GABBAS, P.FOA, A.LOCASCIULLI,C.ROSANELLI,L.CAMBA, P.SARACCO, A. LIPPI, A.P.IORI,F.PORTA, V.DE ROSSI, B.COMOTTI, P.IACOPINO, C.DUFOUR AND A. BACIGALUPO, for the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)* Received 30 March 1999; accepted for publication 23 July 1999 Summary. About 30% of patients with severe aplastic anaemia (SAA) unresponsive to one course of immunosuppressive (IS) therapy with antithymocyte or antilymphocyte globulin can achieve complete or partial remission after a second IS treatment. Among various second-line treatments, rabbit ATG (r-atg) could represent a safe and effective alternative to horse ALG (h-alg). In a multicentre study, 30 patients with SAA (17 males and 13 females, median age 21 years, range 2±67) not responding to a rst course with h-alg plus cyclosporin (CyA) and granulocyte colony stimulating factor (G-CSF), were given a second course using r-atg (3 5 mg/kg/d for 5 d), CyA (5 mg/kg orally from day 1 to 180) and G-CSF (5 mg/kg subcutaneously from day 1 to 90). The median interval between rst and second treatment was 151 d (range 58±361 d). No relevant side-effects were observed, but one patient died early during treatment because of sepsis. Overall response, de ned as transfusion independence, was achieved in 23/30 (77%) patients after a median time of 95 d (range 14±377). Nine patients (30%) achieved complete remission (neutrophils > /l, haemoglobin >11 g/dl and platelets > /l). The overall survival rate was 93% with a median follow-up of 914 d (range 121±2278). So far, no patient has relapsed. Female gender was signi cantly associated with a poorer likelihood to respond (P ˆ ). These data suggest that r-atg is a safe and effective alternative to h-alg for SAA patients unresponsive to rst-line IS treatment. Keywords: aplastic anaemia, immunosuppressive therapy, rabbit antithymocyte globulin, horse antilymphocyte globulin, cyclosporin. Immunosuppressive (IS) therapy based on antilymphocyte (ALG) or antithymocyte globulin (ATG) and cyclosporine (CyA) greatly improved the response rate in patients with severe aplastic anaemia (SAA) not eligible for bone marrow Correspondence: Dr Eros Di Bona, Haematology Department, via Rodol 37, San Bortolo Hospital, I Vicenza, Italy. dibona@hemato.ven.it. transplant (Frickhofen et al, 1991). Furthermore, after the introduction of granulocyte colony stimulating factor (G-CSF), promising results were obtained also in patients with very low neutrophil counts (< /l). In addition to the reduction of early deaths, partial or complete response, de ned as trilineage haematological reconstitution and transfusion independence, was obtained in up to 80% of cases (Bacigalupo et al, 1995). Unfortunately, 10±20% of * Participating centres: Divisione di Ematologia, Ospedale `San Bortolo', Vicenza (E. Di Bona, F. Rodeghiero); Divisione di Ematologia II, Ospedale `San Martino', Genova (B. Bruno, A. Bacigalupo); Divisione di Ematologia, Ospedale Civile, Nuoro (A. Gabbas); Istituto di Scienze Mediche, UniversitaÁ degli Studi, Milano (P. Foa); Clinica Pediatrica, Ospedale `S. Gerardo' (A. Locasciulli); Divisione di Ematologia, Ospedale Generale, Bolzano (C. Rosanelli); Servizio di Ematologia, Ospedale `San Raffaele', Milano (L. Camba); Divisione di Ematologia, Dipartimento di Scienze Pediatriche, UniversitaÁ, Torino (P. Saracco); Ospedale Pediatrico `Meyer', Firenze (A. Lippi); Istituto `Gaslini', Divisione di Medicina IV, Genova (C. Dufour); Divisione di Ematologia, UniversitaÁ `La Sapienza', Roma (A. P. Iori); Clinica Pediatrica, UniversitaÁ, Brescia (F. Porta); Ospedale Pediatrico `Bambin GesuÁ ', Roma (V. De Rossi); Divisione di Ematologia, Ospedali Riuniti, Bergamo (B. Comotti); Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria (P. Iacopino). 330 q 1999 Blackwell Science Ltd
2 patients fail to respond to IS treatment and 30±35% relapse after an initially successful treatment (Schrezenmeier et al, 1993). Some authors have reported consistent data on the ef cacy of retreatment of relapsing or refractory patients with a second IS course. Doney et al (1984) reported response in 3/4 patients relapsing after a second course of ATG. Marsh et al (1987) reported a 22% response rate with rabbit ATG (r-atg) in patients failing a previous course with horse ALG (h-alg). Schrezenmeier et al (1993) reported that half of 74 relapsing patients responded to a second IS treatment. This series included 214 cases failing the rst IS course, 67 of whom were retreated with r-atg, but no separate analysis of these cases was provided. The Vanderbilt University group (Means et al, 1988; Stein et al, 1994) evaluated r-alg as an alternative to h- ALG in 57 patients also receiving prednisone and/or androgens and/or cyclosporin: 8/20 retreated with h-alg after r-alg and 2/8 retreated with r-alg after h-alg responded. Moreover, in a recent single-centre study, 25 patients failing one course of h-alg were treated with a second or more course of h-alg (Tichelli et al, 1998). The response rate was 64% with a % probability of survival at 10 years. Because of its greater supply h-alg is usually the rst choice, but treating patients with a second course of ALG from the same source might increase the risk of allergic reactions. In fact, Tichelli et al (1998) showed an increased rate of acute reactions of immediate hypersensitivity type after retreatment with h-alg (11% v 2%, P ˆ 0 05). Accordingly, a rationale for treating refractory or relapsing patients with ALG from a different animal could be the lower risk of potentially life-threatening allergic reactions. Within the framework of Gruppo Italiano Trapianti di Midollo Osseo (GITMO), patients with SAA have been uniformly treated since 1991 with h-alg, CyA and G-CSF (Bacigalupo et al, 1995). In this study we have analysed the clinical data and outcome of 30 patients failing one IS course of h-alg, CyA and G-CSF who were treated again with a similar IS course substituting h-alg with r-atg. MATERIALS AND METHODS Patients. From 1 October 1991 a total of 100 patients with acquired SAA from 15 different Italian Centres were enrolled in a clinical trial assessing a schedule of h-alg (15 mg/kg i.v., days 1±5), CyA (5 mg/kg, orally, days 1±180) and with G-CSF (5 mg/kg days 1±90). SAA was de ned as hypoplastic bone marrow with <5% blasts, neutrophil count < /l, platelet count < /l and anaemia requiring red blood cell support. For non-responders, bone marrow transplantation, if a suitable donor was available, or second-line therapy with r-atg, CyA and G-CSF, was planned. `Non-responders' were de ned as those patients with pancytopenia requiring blood cell transfusion 120 d after the start of the rst IS course (Bacigalupo et al, 1995). Up to August 1997, 30 non-responders received a second IS course. Clinical details at the time of rst treatment are summarized in Table I. At the time of second IS all patients were dependent on red blood cells and platelet transfusions. Relapsing cases were not included. Second-line Therapy with Rabbit Antithymocyte Globulin in SAA Table I. Clinical characteristics of patients retreated with rabbit ATG. 331 Treatment. Rabbit ATG (Thymoglobulin; Merieux, Lyon, France), 3 5 mg/kg, diluted in isotonic saline, was infused i.v. over 6±8 h from day 1 to 5, according to the manufacturer's instructions; methyl prednisolone 2 mg/kg, from day 1 to 5 and 1 mg/kg from day 6 to 10 was administered i.v. and tapered within 30 d; CyA 5 mg/kg was given orally, from day 1 to 180 and slowly tapered thereafter. 24 patients received G-CSF ( lgrastim) 5 mg/kg subcutaneously, from day 1 to 90. Prophylactic broad-spectrum antibiotics and antimicotics were given orally. Irradiated platelet concentrates and packed red blood cells were given for platelet < /l and Hb <8 5 g/dl. Response. Patients were assessed for clinical response 180 d after the start of the second IS course. A period of transfusion independence of at least 1 month was required to de ne a case as a responder. Patients were classi ed as complete responders if they had a neutrophil count > /l, platelet count > /l and a haemoglobin level 11 g/dl; partial responders if they had neutrophil count > /l, platelet count > /l and a haemoglobin level >8 g/dl. Statistical analysis. All the patients entered descriptive, univariate and multivariate analysis. Survival was calculated by the Kaplan-Meier method. Two patients who received bone marrow transplantation (BMT) were censored at that time. RESULTS Median Range Age (years) ±67 Sex (male/female) 17/13 Neutrophils ( 10 9 /l) 0 2 0±5 Platelets ( 10 9 /l) 5 1±33 Haemorrhages (yes/no) 14/16 Infection (yes/no) 11/19 Interval between diagnosis 27 4±457 and rst treatment (d) Interval between rst and ±361 second treatment (d) Follow-up (d) ±2278 Overall, the treatment was well tolerated; no anaphylactic reactions or severe side-effects were recorded. Seven patients (23%), all female, remained transfusion dependent with minimal improvement in their blood cell counts. Two (6 6%) of them died. The rst, a 67-year-old woman died because of sepsis 30 d after r-atg. The second, a 13-year-old girl, died of infection (neutrophil count < /l) 1 year after treatment. One patient underwent allogeneic bone marrow transplant (BMT) from HLA-matched unrelated donor 21 months after treatment. 23 patients (77%) became transfusion independent after a median time of 95 d (range 14±377). Nine patients (30%) had a complete response, after a median time of 61 d
3 332 E. Di Bona et al Table II. Haematological recovery in partial and complete responders (median and range values). Partial Complete P Patients (n) 14 9 Sex (male/female) 10/4 7/2 0 7 Haemoglobin (g/dl) 11 8 (9 7±15) 13 (11 5±15) 0 1 Neutrophils ( 10 9 /l) 1 3 (0 2±2 3) 2 1 (2±5) Platelets ( 10 9 /l) 58 (40±117) 140 (100±212) Interval between 167 (58±226) 126 (89±361) 0 3 rst and second treatment (d) Interval between 150 (23±377) 61 (14±196) 0 04 second treatment and response (d) Fig 1. Response after rabbit ATG. (range 14±196); 14 (47%) achieved partial remission after a median period of 150 d (range 23±377) (Fig 1). 10 patients werere-treatedbetween85and120d(tablei)afterthe rstis course on a clinical basis by at the discretion of the attending physician. No difference in response rate (7/10 v 16/20) or in the median time to response(941 v 1055 d, P not signi cant) was observed between this group of patients and those treated 120 d after the rst course. No difference was observed between partial and complete responders apart from time to response (150 v 61 d, respectively, P ˆ 0 04) (Fig 2). One partial responder received allogeneic BMT 18 months after the start of treatment. Of the six patients who did not receive G- CSF, two were non-responders, one partial and three complete responders. At the last observation, 7/23 (30%) responders were not receiving any drug, after a mean period of 27 months (range 9±34) since the last transfusion. Most patients with partial (10/12) and complete (4/9) response continued cyclosporine with or without tailored dosage of G-CSF for a mean period of 23 months (range 0 7±69) since the last transfusion. Recovery of neutrophil and platelet count was signi cantly different in partial and complete responders (Table II). All patients had a normal cytogenetic pro le demonstrated at diagnosis or sometimes during the rst 6 months of follow-up period and at the last observation. Three patients developed a clonal disease: two myelodysplasia (6 5%) and one monoclonal gammopathy of unde ned signi cance (3%). No relapses have been observed to date. The only response-in uencing variable was sex; 7/13 women were unresponsive, whereas all males responded (P ˆ , Fisher exact test). The median follow-up for surviving patients is 914 d (range 121±2278). Actuarial survival is 93% (Fig 3): 100% for responders and 71% for not responders (P ˆ 0 01). Survival was not in uenced by sex (100% and 85% for male and female respectively), age, interval between diagnosis and rst treatment or between rst and second treatment, complete or partial response. Fig 3. Overall survival after rabbit ATG in a cohort of 30 patients not responding to a rst immunosuppressive course with horse ALG, cyclosporin and lgrastim. DISCUSSION Fig 2. Time to response after rabbit ATG according to partial (14 cases) or complete (nine cases) response. The difference is statistically signi cant (P ˆ 0 04). We have shown in this study that SAA patients not responsive to rst-line intensive IS treatment have a 77% chance of achieving remission and a 93% chance of survival
4 after r-atg based second-line treatment. Median follow-up of surviving patients is 30 months. No anaphylaxis or major symptoms of allergic reaction were recorded. Other reports have examined the effectiveness of a second course of ATG (Doney et al, 1984; Marsh et al, 1987; Means et al, 1988; Schrezenmeier et al, 1993, 1995; Stein et al, 1994; Tichelli et al, 1998). The present series, although limited in number, is unique for the following reasons: all patients received the same rst-line therapy, consisting of h-alg, CyA, G-CSF (Bacigalupo et al, 1995); all patients received r-atg as second-line treatment in association with CyA with or without and G-CSF; all patients were treated and followed prospectively within the same co-operative group. Whether some of these patients would have responded in the absence of a second-line therapy seems unlikely. In fact, the interval between ALG and response in rst- and second-line therapy was the same. In our series the probability of becoming transfusion independent was similar after the rst course with h-alg or after retreatment with r-atg (70% v 77%, respectively). Furthermore, Tichelli et al (1998) have con rmed the ef cacy of a second or subsequent course with h-alg, reporting a 63% response rate, completely superimposable to that obtained after the rst course (89/139, 64%). These data suggest that retreatment withalgiseffectiveandthatr-atghasatleastthesame ef cacy when compared with h-alg. In contrast to Tichelli et al (1998), who reported a signi cant higher rate of acute reactions (11% v 2%, P ˆ 0 05), no relevant immediate or late side-effects were observed after r-atg. Twenty-three patients achieved transfusion independence. Time to response was similar to that reported in rst-line therapy with h-alg (Bacigalupo et al, 1995). 50% of the patients responded within 95 d, but the range was wide and transfusion independence was achieved in 90% of the patients within 1 year after treatment. Our ndings are similar to that reported by Tichelli et al (1998), who found 8/27 responding patients with haematological recovery after 6 months or more. Slow responders were often partial responders; partial and complete responders differed in time to response and in haematological recovery (Table II). The different quality of haematological recovery may be due to the various pathogenic mechanisms involved in AA (Young & Maciejewski, 1997). This is in keeping with the residual abnormalities of haemopoiesis observed in vitro (i.e. proliferative capacity of haemopoietic progenitors) (Bacigalupo et al, 1993; PodestaÁ et al, 1998; Piaggio et al, 1998). At the last follow-up, only 33% of responders were off therapy, whereas most continued cyclosporine with or without tailored dosage of G-CSF. The long-lasting treatment may explain the absence of relapses. It is known that some patients may relapse after the discontinuation of therapy with CyA (Gluckman et al, 1992; A. Bacigalupo, personal communication) and that discontinuation of G-CSF induces a dramatic reduction of the neutrophil count. Female gender appeared the only factor predicting failure, suggesting an hormonal in uence. No differences were observed between males and females as to WBC, platelet count, age at the time of the rst therapy, time to the rst treatment, interval between treatments. A different response Second-line Therapy with Rabbit Antithymocyte Globulin in SAA 333 rate between males and females has been reported in a randomized study comparing the effectiveness of h-alg with or without androgens (Bacigalupo et al, 1993). Responding females were 20% v 39% of males in the group treated with h-alg alone, but the adjunct of androgen conferred a signi cant higher advantage to female gender (60% v 43%). Evolution to a clonal haematological disorder is matter of concern. The incidence of myelodysplasia, acute leukaemia or solid neoplasm after one or more immunosuppressive courses varied between about 10% (De Planque et al, 1989; Socie et al, 1993) and 40%, including paroxysmal nocturnal haemoglobinuria (Tichelli et al, 1998). The degree of immunosuppression could play a role in clonal evolution. Tichelli et al (1998) have found a slight, but not signi cant, difference between patients exposed to one or more immunosuppressive courses (34% and 53% respectively, P ˆ 0 2), whereas Socie et al (1993) reported a higher risk (relative risk 2 26, P ˆ 0 03) after repeated courses. Although the number of patients was small, we observed a clonal disorder only in 10% of the cases after a second IS therapy with r-atg, CyA and G-CSF. Furthermore, in our series, in keeping with data reported by De Planque et al (1989), the development of a clonal disorder did not in uence survival. Actually, given the high incidence of myelodysplastic features in peripheral blood and bone marrow at diagnosis (Tichelli et al, 1992), it is sometimes dif cult to distinguish between hypoplastic myelodysplastic syndrome and aplastic anaemia on morphological grounds. The presence of cytogenetic abnormalities strictly correlate with clonal evolution (Mikhailova et al, 1996) and cytogenetics combined with uorescent in situ hybridization should be used to reveal non-random chromosomal abnormalities (La Starza et al, 1998). In conclusion, although a control arm was not included, our data support the use of rabbit ATG as second-line treatment for patients failing to respond to IS treatment based on horse ALG. The high rate of responses in this negatively selected group of patients warrants a randomized prospective trial comparing rabbit ATG to horse ALG as a rst choice. The excellent survival suggests that, at present, bone marrow transplant from a non-sibling donor should be postponed to third-line therapy. REFERENCES Bacigalupo, A., Broccia, A., Corda, G., Arcese, W., Carotenuto, M., Gallamini, A., Locatelli, F., Mori, G.P., Saracco, P., Todeschini, G., Coser, P., Iacopino, P., van Lint, M.T. & Gluckman, E. (1995) Antilymphocyte globulin, cyclosporin, and granulocyte colonystimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party. Blood, 85, 1348±1353. Bacigalupo, A., Chaple, M., Hows, J., van Lint, M.T., McCann, S., Milligan, D., Chessel, J., Goldstone, A.H., Ottolander, J., van't Veer, E.T., Comotti, B., Coser, P., Broccia, G., Bosi, A., Locasciulli, A., Catalano, M., Battista, R., Arcese, W., Carotenuto, M., Marmont, A.M. & Gordon-Smith, E.C. (1993) Treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (Mpred) with or without androgens: a randomized trial for EBMT SAA working party. British Journal of Haematology, 83, 145± 151.
5 334 E. Di Bona et al De Planque, M.M., Bacigalupo, A., Wursh, A., Hows, J.M., Devergie, A., Frickhofen, N., Brand, A. & Nissen, C. (1989) Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. British Journal of Haematology, 73, 121±126. Doney, K., Dahlberg, S.J., Monroe, D., Storb, R., Buckner, C.D. & Thomas, E.D. (1984) Therapy of severe aplastic anemia with antihuman thymocyte globulin and androgens: the effect of HLA haploid identical marrow infusion. Blood, 63, 342±348. Frickhofen, N., Kaltwasser, J.P., Schrezenmeier, H., Raghavachar, A., Vogt, H.G., Herrmann, F., Freun, M., Meusers, P., Salama, A. & Heimpel, H. (1991) Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. New England Journal of Medicine, 324, 1297±1304. Gluckman, E., Esperou-Bourdeau, H., Baruchel, A., Boogaerts, M., Briere, J., Donadio, D., Leverger, G., Leporrier, M., Reiffers, J., Janvier, M., Michallet, M. & Stryckmans, P. (1992) Multicenter randomized study comparing cyclosporine A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood, 79, 2540±2546. La Starza, R., Matteucci, C., Crescenzi, B., Criel, A., Selleslag, D., Martelli, M.F., Van den Berghe, H. & Mecucci, C. (1998) Trisomy 6 is the hallmark of a dysplastic clone in bone marrow aplasia. Cancer Genetics and Cytogenetics, 105, 55±59. Marsh, J.C.W., Hows, J.M., Briett, K.A., Al-Hashimi, S., Fairhead, S.M. & Gordon-Smith, E.C. (1987) Survival after antilymphocyte globulin therapy depends on disease severity. Blood, 70, 1046±1052. Means, R.T., Jr, Krantz, S.B., Dessypris, E.N., Luckens, J.N., Niblack, G.D., Greer, J.P., Flexner, J.M. & Stein, R.S. (1988) Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. American Journal of Medicine, 84, 678±682. Mikhailova, N., Sessarego, M., Fugazza, G., Caimo, A., De Filippi, F., van Lint, M.T., Bregante, S., Valeriani, A., Mordini, N., Lamparelli, T., Gualandi, F., Occhini, D. & Bacigalupo, A. (1996) Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica, 81, 418±422. Piaggio, G., PodestaÁ, M., Pitto, A., Pittalunga, G.B., Isaza, A., Benvenuto, F., Bruno, B. & Bacigalupo, A. (1998) Comparable TNF-alfa, IFN-gamma and GM-CSF production by puri ed normal marrow CD3 cells in response to horse antilymphocyte and rabbit antithymocyte globulin. European Journal of Haematology, 60, 240±244. PodestaÂ, M., Piaggio, G., Frassoni, F., Pitto, A., Zikos, P., Sessarego, M., Abate, M., Van Lint, M.T., Berisso, G. & Bacigalupo, A. (1998) The assessment of the hematopoietic reservoir after immunosuppressive therapy of bone marrow transplantation in severe aplastic anemia. Blood, 91, 1959±1965. Schrezenmeier, H., Hinterberger, W., Hows, J., Ljungman, P., Locasciulli, A., Marin, P., Marsh, J., McCann, S., den Ottolander, G.J., Raghavachar, A., Socie, G., Tichelli, A., Van't Veer-Korthof, E.T. & Bacigalupo, A., for the EBMT SAA Working Party (1995) Second immunosuppressive treatment of patients with aplastic anemia not responding to the rst course of immunosuppression: a report from the Working Party on severe aplastic anemia of the EBMT. Bone Marrow Transplantation, 15, (Suppl. 1), S10. Schrezenmeier, H., Marin, P., Raghavachar, A., McCann, S., Hows, J., Gluckman, E., Nissen, C., Van't Veer-Korthof, E.T., Ljungman, P., Hinterberger, W., Van Lint, M.T., Frickhofen, N. & Bacigalupo, A. (1993) Relapse of aplastic anaemia after immunosuppressive treatment: a report from European Bone Marrow Transplantation group SAA working party. British Journal of Haematology, 85, 371± 377. Socie, G., Henry-Amar, M., Bacigalupo, A., Hows, J., Tichelli, A., Ljungman, P., McCann, S.R., Frickhofen, N., Van't Veer-Korthof, E.T. & Gluckman, E., for the European Bone Marrow Transplantation±Severe Aplastic Anaemia Working Party (1993) Malignant tumors occurring after treatment of aplastic anemia. New England Journal of Medicine, 329, 1152±1157. Stein, R.S., Means, R.T., Jr, Krantz, S.B., Flexner, J.M. & Greer, J.P. (1994) Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. American Journal of the Medical Sciences, 308, 338±343. Tichelli, A., Gratwohl, A., Nissen, C., Signer, E., Stebler Gysi, C. & Speck, B. (1992) Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood, 80, 337± 345. Tichelli, A., Passweg, J., Nissen, C., Bargetzi, M., Hoffmann, T., Wodnar-Filipowicz, A., Signer, E., Speck, B. & Gratwohl, A. (1998) Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. British Journal of Haematology, 100, 393±400. Young, N.S. & Maciejewski, J. (1997) The pathophysiology of acquired aplastic anemia. New England Journal of Medicine, 336, 1365±1372.
Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin
Brazilian Journal of Medical and Biological Research (2000) 33: 553-558 ATG in aplastic anemia ISSN 0100-879X 553 Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More informationAcquired severe aplastic anemia (SAA)
[haematologica] 2004;89:1052-1061 Aplastic anemia Research Paper Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens:
More informationImproved prognosis for acquired aplastic anaemia
158 Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK L A Pitcher I M Hann JPMEvans P Veys J M Chessells DKHWebb Correspondence to: Dr Webb.
More informationThis paper provides an algorithmic
medical decision making and problem solving in hematology Haematologica 1994; 79:438-444 GUIDELINES FOR THE TREATMENT OF SEVERE APLASTIC ANEMIA Andrea Bacigalupo for the Working Party on Severe Aplastic
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationIN PATIENTS WITH APLASTIC ANEMIA,
ORIGINAL CONTRIBUTION Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia Association Between Hematologic Response and Long-term Outcome Stephen Rosenfeld, MD Dean Follmann, PhD Olga Nunez,
More informationIn Vitro Effect of Stem Cell Factor on Colony Growth from Acquired Severe Aplastic Anemia
In Vitro Effect of Stem Cell Factor on Colony Growth from Acquired Severe Aplastic Anemia A. Bacigalupo," G. Piaggio," M. Podestd," M. R. Raffo," E. Tedone," G. Sogno," E Benvenuto,". Figari," L. Grassia,"
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationInt J Clin Exp Med 2015;8(9): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(9):16334-16339 www.ijcem.com /ISSN:1940-5901/IJCEM0011065 Original Article Not all anti-t lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly
More informationShould we still use Camitta s criteria for severe aplastic anemia?
VOLUME 47 ㆍ NUMBER 2 ㆍ June 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Should we still use Camitta s criteria for severe aplastic anemia? Hyun Hwa Yoon, Seok Jae Huh, Ji Hyun Lee, Suee Lee,
More informationLong-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin
Published Ahead of Print on July 13, 2017, as doi:10.3324/haematol.2017.171215. Copyright 2017 Ferrata Storti Foundation. Long-term risk of cancer development in adult patients with idiopathic aplastic
More informationAplastic Anemia: Management of Adult Patients
Aplastic Anemia: Management of Adult Patients Jaroslaw P. Maciejewski and Antonio M. Risitano The primary therapeutic approach to acquired aplastic anemia (AA) in older adults differs from the primary
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationFirst line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated
Received: 30 January 2018 Revised: 24 February 2018 Accepted: 26 February 2018 DOI: 10.1002/ajh.25081 RESEARCH ARTICLE First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationImmunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel
Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem
More informationA promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic anemia
Ann Hematol (2013) 92:1239 1247 DOI 10.1007/s00277-013-1764-7 ORIGINAL ARTICLE A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate
More informationAplastic anemia is a bone-marrow failure. Survival After Immunosuppressive Therapy in Children with Aplastic Anemia
R E S E A R C H P A P E R Survival After Immunosuppressive Therapy in Children with Aplastic Anemia VELU NAIR, * VISHAL SONDHI, $ AJAY SHARMA, $ SATYARANJAN DAS AND $ SANJEEVAN SHARMA From the Department
More informationHorse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
The new england journal of medicine original article Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia Phillip Scheinberg, M.D., Olga Nunez, R.N., B.S.N., Barbara Weinstein, R.N.,
More informationPacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!
Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationThe evaluation of acquired aplastic anemia in children and unexpected frequency of varicella-zoster virus association: a single-center study
The Turkish Journal of Pediatrics 2008; 50: 342-348 Original The evaluation of acquired aplastic anemia in children and unexpected frequency of varicella-zoster virus association: a single-center study
More informationIntroduction. Patients and methods
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationAplastic anemia: therapeutic updates in immunosuppression and transplantation
IMMUNE DYSREGULATION Aplastic anemia: therapeutic updates in immunosuppression and transplantation Phillip Scheinberg 1 1 Hematology Branch, National Heart, Lung and Blood Institute, National Institutes
More informationManagement of acquired aplastic anemia in children
Management of acquired aplastic anemia in children Korthof, E. T.; Békássy, Albert; Hussein, A. A. Published in: Bone Marrow Transplantation DOI: 10.1038/bmt.2012.235 Published: 2013-01-01 Link to publication
More informationIncidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Incidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults Ji
More informationREPORT. KEY WORDS: Severe aplastic anemia, Blood and marrow transplantation, Immunosuppressive therapy, Telomeres
REPORT Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More informationresearch paper Summary
research paper Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant Summary This
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 ANTILYMPHOCYTE GLOBULINS FRESENIUS 20 mg/ml, solution to dilute for infusion 10 glass bottle(s) of 5
More informationNontransplant therapy for bone marrow failure
Nontransplant therapy for bone marrow failure Danielle M. Townsley and Thomas Winkler BONE MARROW FAILURES Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD Nontransplant therapeutic
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationCase Report Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia
Case Reports in Gastrointestinal Medicine Volume 2012, Article ID 395801, 6 pages doi:10.1155/2012/395801 Case Report Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit
More informationmyelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationElias Hallack Atta, 1 Adriana Martins de Sousa, 1 Marcelo Ribeiro Schirmer, 1 Luis Fernando Bouzas, 1 Marcio Nucci, 2 Eliana Abdelhay 1
Different Outcomes between Cyclophosphamide Plus Horse or Rabbit Antithymocyte Globulin for HLA-Identical Sibling Bone Marrow Transplant in Severe Aplastic Anemia Elias Hallack Atta, 1 Adriana Martins
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationMaking Therapeutic Decisions in Adults with Aplastic Anemia
Making Therapeutic Decisions in Adults with Aplastic Anemia Judith Marsh The management of adults presenting with aplastic anemia (AA) requires careful exclusion of other causes of bone marrow failure.
More informationAplastic Anemia and Monosomy 7 Associated Dysmegakaryocytopoiesis
Hematopathology / APLASTIC ANEMIA AND DYSMEGAKARYOCYTOPOIESIS Aplastic Anemia and Monosomy 7 Associated Dysmegakaryocytopoiesis Michelle M. Dolan, MD, 1 Timothy P. Singleton, MD, 1 Joseph Neglia, MD, MPH,
More informationP atients with acute graft-versus-host disease (GvHD) grade I were
Cell Therapy & Immunotherapy ARTICLE Steroid treatment of acute graft-versus-host disease grade I: a randomized trial Andrea Bacigalupo, 1 Giuseppe Milone, 2 Alessandra Cupri, 2 Antonio Severino, 3 Franca
More informationBone marrow failure syndromes
11 Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6. 12 Harrison CN, Campbell PJ, Buck G, Wheatley K et al. A randomised comparison
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationIIE 1. Transplantation for PNH; single centers experience. Data was analyzed on 67
IIE 1. Transplantation for PNH; single centers experience. Data was analyzed on 67 patients from the cited literature with special attention to eliminating duplicate reporting of patients 1-24. Of these
More informationMatched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation?
HEMATOPOIETIC STEM CELL TRANSPLANTATION I: EXPLOITING ALTERNATIVE DONORS Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? Andrea
More informationEffect of Interleukin 10 on the Hematopoietic Progenitor Cells from Patients with Aplastic Anemia
Effect of Interleukin 10 on the Hematopoietic Progenitor Cells from Patients with Aplastic Anemia YOSHINOBU ASANO, SHOICHIRO SHIBATA, SHINJI KOBAYASHI, SEIICHI OKAMURA, YOSHIYUKI NIHO First Department
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationMarrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy
Biology of Blood and Marrow Transplantation 5:243 252 (1999) 1999 American Society for Blood and Marrow Transplantation ASBMT #48 Marrow transplantation from unrelated donors for patients with severe aplastic
More informationIn vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia
Washington University School of Medicine Digital Commons@Becker Open Access Publications 214 In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia Xingmin Feng
More informationOUTCOME AFTER IMMUNOSUPPRESSION
OUTCOME AFTER IMMUNOSUPPRESSION EBMT Aplastic Anemia Educational Meeting Budapest November 1 st 2012 Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplant Unit Hematology, DBBM Federico II University
More informationS peripheral pancytopenia due to unexpected failure of
Morphology in Patients With Severe Aplastic Anemia Treated With Antilymphocyte Globulin By Andre Tichelli, Alois Gratwohl, Catherine Nissen, Erich Signer, Christine Stebler Gysi, and Bruno Speck One hundred
More informationMyelodysplastic syndromes
Haematology 601 Myelodysplastic syndromes The myelodysplastic syndromes are a group of disorders predominantly affecting elderly people, leading to ineffective haematopoiesis, and they have the potential
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationPeinemann F, Bartel C, Grouven U. Cochrane Database of Systematic Reviews. Peinemann F, Bartel C, Grouven U.
Cochrane Database of Systematic Reviews First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationCase Report Dynamics of Graft Function Measured by DNA-Technology in a Patient with Severe Aplastic Anemia and Repeated Stem Cell Transplantation
Case Reports in Medicine, Article ID 576373, 5 pages http://dx.doi.org/10.1155/2014/576373 Case Report Dynamics of Graft Function Measured by DNA-Technology in a Patient with Severe Aplastic Anemia and
More informationMarrow Transplants From Unrelated Donors for Patients With Aplastic Anemia: Minimum Effective Dose of Total Body Irradiation
Biology of Blood and Marrow Transplantation 7:208-215 (2001) 2001 American Society for Blood and Marrow Transplantation ASBMT Marrow Transplants From Unrelated Donors for Patients With Aplastic Anemia:
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,
More informationManagement of acquired aplastic anemia in children
Bone Marrow Transplantation (2013) 48, 191 195 & 2013 Macmillan Publishers Limited All rights reserved 0268-3369/13 www.nature.com/bmt REVIEW Management of acquired aplastic anemia in children ET Korthof
More informationArticles and Brief Reports
Articles and Brief Reports Stem Cell Transplantation Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin
More informationWITH THE CHARACTERIZATION in the 1960s of the
Long-Term Outcome After Marrow Transplantation for Severe Aplastic Anemia By H. Joachim Deeg, Wendy Leisenring, Rainer Storb, Janet Nims, Mary E.D. Flowers, Robert P. Witherspoon, Jean Sanders, and Keith
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationCMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus
CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus Małgorzata Mikulska, 1 Anna Maria Raiola, 2 Paolo Bruzzi, 3 Riccardo
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More informationDIFFERENTIAL ASSAYS USED IN STUDY OF NATURAL KILLER CELL CYTOTOXICITY ASSAY. D.S.Vani Sri and B.Venkatappa
DOI: 10.21276/ijabpt.2016.7.4.18 Volume-7, Issue-4, Oct-Dec-2016 Coden IJABFP-CAS-USA Copyrights@2016 Received: 17 th Aug 2016 Revised: 30 th Sept 2016 Accepted: 3 rd Oct 2016 DOI: 10.21276/Ijabpt, http://dx.doi.org/10.21276/ijabpt
More informationAplastic anaemia in childhood. Description of two cases and review of the literature
Cent. Eur. J. Med. 4(3) 2009 363-368 DOI: 10.2478/s11536-009-0024-7 Central European Journal of Medicine Aplastic anaemia in childhood. Description of two Maria Scalzone, Paola Coccia, Palma Maurizi, Giorgio
More informationhematology Board Review Manual
Volume 6, Part 1 april 2011 hematology Board Review Manual Aplastic Anemia: Review Questions Merck is pleased to provide this material as a professional service to the medical community. The Hospital Physician
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationThe use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationAtgam (lymphocyte immune globulin, anti-thymocyte globulin [equine])
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.01 Subject: Atgam Page: 1 of 5 Last Review Date: June 24, 2016 Atgam Description Atgam (lymphocyte
More informationCase Report Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab
Case Reports in Hematology Volume 212, Article ID 16182, 5 pages doi:1.1155/212/16182 Case Report Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab Radha Raghupathy
More informationSevere Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018
Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but
More informationImmunosuppressive therapy for aplastic anemia: a single-center experience from western India
Annals of Hematology https://doi.org/10.1007/s00277-018-3487-2 ORIGINAL ARTICLE Immunosuppressive therapy for aplastic anemia: a single-center experience from western India Sandip Shah 1 Asha Anand 1 &
More informationHepatitis Associated Aplastic Anaemia: Epidemiology and Treatment Results obtained in Europe. A Report of The EBMT Aplastic Anemia Working Party
Hepatitis Associated Aplastic Anaemia: Epidemiology and Treatment Results obtained in Europe. A Report of The EBMT Aplastic Anemia Working Party Anna Locasciulli, Andrea Bacigalupo, Barbara Bruno, Barbara
More informationMarrow graft rejection and inhibition of growth in culture by serum in aplastic anaemia
Journal of Clinical Pathology, 1978, 31, 1244-1248 Marrow graft rejection and inhibition of growth in culture by serum in aplastic anaemia A. J. BARRETT', A. FAILLE, F. SAAL, N. BALITRAND, AND E. GLUCKMAN
More informationCurrent management of severe acquired aplastic anemia
REVIEW Current management of severe acquired aplastic anemia Tratamento atual da anemia aplástica adquirida grave Phillip Scheinberg 1 ABSTRACT Overall survival in severe aplastic anemia has markedly improved
More informationUnrelated allogeneic transplantation for severe aplastic anemia is a treatment
ARTICLE Stem Cell Transplantation EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More informationDisclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017
2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 2 Dr Helen Barker MDT Lead
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationRelationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored proteindeficient
British Journal of Haematology, 2001, 115, 1015±1022 Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored proteindeficient clones Jaroslaw P. Maciejewski,
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationRAPID PUBLICATION. KEY WORDS: Bone marrow transplantation, Stem cell transplantation, Matched unrelated donor, Antithymocyte globulin
RAPID PUBLICATION Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening
More informationDoes anti-thymocyte globulin have a place in busulfan/fludarabine
ORIGINAL ARTICLE Korean J Intern Med 2016;31:750-761 Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Young
More informationUmbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Stem Cell Transplantation SUPPLEMENTARY APPENDIX Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia José Luis Piñana,
More informationARTICLES. Introduction
ARTICLES Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationJong Wook Lee, Byung Sik Cho, Sung Eun Lee, Ki Seong Eom, Yoo Jin Kim, Hee Je Kim, Seok Lee, Chang Ki Min, Seok Goo Cho, Woo Sung Min, Chong Won Park
The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cgy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia Jong Wook Lee,
More informationAplastic Anemia: Management of Pediatric Patients
Aplastic Anemia: Management of Pediatric Patients Eva C. Guinan Aplastic anemia is a term describing the common findings of pancytopenia and marrow hypoplasia arising from a variety of disease states,
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationImatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationAplastic Anemia and related bone marrow failures. Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA
Aplastic Anemia and related bone marrow failures Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA CONFLICTS OF INTEREST Advisory Board meetings: Merck,
More informationAplastic Anemia and related bone marrow failures. Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA
Aplastic Anemia and related bone marrow failures Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA CONFLICTS OF INTEREST Advisory Board meetings: Merck,
More information